Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder that affects males. However, 8% of female carriers are symptomatic and underrepresented in research due to the lack of animal models. We generated a symptomatic mouse model of DMD carriers via injection of mdx (murine DMD) embryonic stem cells (ESCs) into wild-type (WT) blastocysts (mdx/WT chimera). mdx/WT chimeras developed cardiomyopathic features and dystrophic skeletal muscle phenotypes including elevated mononuclear invasion, central nucleation, fibrosis and declined forelimb grip strength. The disease was accompanied by connexin-43 (Cx43) aberrantly enhanced in both cardiac and skeletal muscles and remodeled in the heart. Genetic reduction of Cx43-copy number in mdx/WT-Cx43(+/−) chimeras protected them from both cardiac and skeletal muscle fiber damage. In dystrophic skeletal muscle, Cx43 expression was not seen in the fibers but in adjacent F4/80+ mononuclear cells. Ethidium Bromide uptake in purified F4/80+/CD11b+ mdx macrophages revealed functional activity of Cx43, which was inhibited by administration of Gap19 peptide mimetic, a Cx43 hemichannel-specific inhibitor. Thus, we suggest that Cx43 reduction in symptomatic DMD carrier mice leads to prevention of Cx43 remodeling in the heart and prevention of aberrant Cx43 hemichannel activity in the skeletal muscle macrophages neighboring Cx43 non-expressing fibers. Duchenne muscular dystrophy (DMD) is an incurable X-linked recessive disorder characterized by mutations in the dystrophin gene. The dystrophin protein is an essential part of the dystrophin-glycoprotein complex (DGC), which provides structure and mechanically-induced signal propagation between intracellular and extracellular environments 1. X-linked disorders only affect male patients; however, a percentage of female DMD heterozygotes are symptomatic. Symptomatic female carriers consist of about 8-40% of definite DMD carriers and begin to present symptoms between the ages of 2-47 years old 2,3. Patients display a range of severe to less severe phenotypes. It is generally accepted to affect 8% of female carriers, yet this statistic aligns with those affected by dilated cardiomyopathy. A higher percentage (17%) suffer from muscle weakness 3-10. Heart complications can be further expanded to include left-ventricle dilation (40%) 10. Research on symptomatic carriers has been confined to clinical observations largely due to the absence of a representative animal model 2,3,9,11,12. These epidemiological studies are subject to a larger margin of error from confounding variables, necessitating a DMD animal model that successfully recapitulates the symptomatic carrier phenotypes and mosaicism. X-linked muscular dystrophy mice (mdx) 13 heterozygotes, mdx(+/−), show normal muscle histology and do not develop cardiomyopathy 11,12. Recently, we described the generation of a model to study symptomatic DMD carriers that faithfully recapitulates the pathology and symptoms (mdx/WT mouse chimeras) 14. Symptomatic mdx mouse chimeras were ...